Related Experiment Videos

[Antiatherosclerotic hopes of calcium channel blockers]

Yuzaburo Uetake1, Tatsuo Shimosawa

  • 1Graduate school of Medicine, Department of Internal Medicine, Nephrology and Endocrinology, The University of Tokyo.

Clinical Calcium
|October 4, 2005
PubMed

Insights

Dihydropyridine calcium channel blockers demonstrate antiatherosclerotic effects beyond blood pressure reduction. These effects stem from antioxidant properties and direct actions on vascular cells, supported by clinical trials.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Cell Biology

Context:

  • Atherosclerosis is a significant cardiovascular disease.
  • Calcium channel blockers (CCBs) are widely used antihypertensive drugs.
  • Emerging evidence suggests CCBs may possess direct antiatherosclerotic properties.

Purpose:

  • To review the antiatherosclerotic effects of CCBs.
  • To elucidate the mechanisms underlying these effects.
  • To discuss the clinical relevance of these findings.

Summary:

  • Animal studies indicate that dihydropyridine CCBs exhibit antiatherosclerotic effects.
  • Mechanisms include antioxidant properties and direct actions on vascular cells, independent of blood pressure lowering.
  • Randomized clinical trials like PREVENT and CAMELOT provide further evidence supporting these effects.

Impact:

  • Highlights the potential of CCBs in managing atherosclerosis.
  • Suggests a broader therapeutic role for CCBs in cardiovascular disease.
  • Informs future research and clinical practice regarding CCB use in atherosclerosis prevention and treatment.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...